Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Ochrona przed dezinformacją na temat szczepionek przeciwko wirusowi HIV wśród dorastających dziewcząt i młodych kobiet w Republice Południowej Afryki (PROTECT)

28 sierpnia 2026 zaktualizowane przez: University of Pennsylvania

Adolescent girls and young women (AGYW) between the ages of 15-29 years continue to bear the brunt of Human Immunodeficiency Virus (HIV) infections in South Africa despite progress recorded in prevention and treatment programmes. The ongoing susceptibility of young women to HIV infection and the sub-optimal uptake of prevention options such as Pre-Exposure Prophylaxis (PrEP) that are highly effective creates a need for an HIV vaccine to benefit populations at substantial risk of HIV infection. However, lessons from previous vaccine studies and the recent COVID-19 vaccine have highlighted significant barriers to vaccine uptake, such as widespread misinformation and vaccine hesitancy. These challenges threaten the successful implementation of a future HIV vaccine. Building on these insights, this study will utilise psychological inoculation theory to develop and evaluate HIV vaccine messages among adolescent girls and young women. Primary objective: To compare changes in intentions to receive HIV vaccine following misinformation exposure in groups with and without psychological inoculation and behavioural economics boost.

Secondary objectives: (1) To compare believability and persuasiveness of misinformation claims and motivational threat associated with misinformation in groups with and without psychological inoculation and behavioural economics boost. (2) To explore subgroup effects by relevant sociodemographic and behavioural factors including HIV risk, PrEP history, COVID-19 vaccine history, general vaccine hesitancy, and information avoidance. The investigators will conduct a two-arm randomized controlled trial of 2-3 inoculation messages that address emerging myths and misinformation about the HIV vaccine in South Africa. Participants will be randomly assigned to a control group or an intervention arm: enhanced inoculation message with insights from behavioural economics.

Przegląd badań

Status

Aktywny, nie rekrutujący

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

2163

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Johannesburg, Afryka Południowa
        • Health Economics and Epidemiology Research Office, University of the Witwatersrand

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 29 lat (Dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Female
  • Age 18-29 years
  • Self-reported history of sexual activity in the past 12 months
  • Self-reported HIV-negative status or unknown HIV status at enrolment
  • Willing and able to provide written informed consent
  • Able to read and understand English

Exclusion Criteria:

  • Unwilling or unable to provide consent for study participation.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Control

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Participants enrolled in the control group will receive unrelated information on diabetes and nutrition topics of the same length as the inoculation messages. Please see Appendix 6 for an example of how this message will be structured. This will make the control group an attention control group and ensure that findings are not confounded by the intervention group spending more time and attentional resources on participation in the study.

Inny: Enhanced inoculation message

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Participants enrolled in the enhanced inoculation message arm will receive messages that warn them about impending HIV vaccine misinformation and explains why those claims are false or misleading, the messages will be enhanced with insights from behavioural economics see Appendix 5: "Inoculation message with a BE boost" for an example of the inoculation message. As part of the behavioural economics boost, participants may choose to receive a small token (e.g., sticker, badge, bracelet) with a message promoting vaccination as a consistency and commitment prime.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
HIV Vaccine Intention, at the End of the Baseline Assessment
Ramy czasowe: At the end of the baseline assessment

Intention to get the HIV vaccine, measured after inoculation intervention and misinformation exposure The intention to get the vaccine will be measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

At the end of the baseline assessment

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
HIV Vaccine Intention, Follow-up
Ramy czasowe: 2-4 weeks

Intention to get the HIV vaccine, measured at follow-up survey following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to get the HIV vaccine.

2-4 weeks
Recommend to Friends, at the End of the Baseline Assessment
Ramy czasowe: At the end of the baseline assessment

Intention to recommend the HIV vaccine to friends, measured at survey baseline following misinformation exposure and intervention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

At the end of the baseline assessment
Recommend to Friends, Follow-up
Ramy czasowe: 2-4 weeks

Intention to recommend the HIV vaccine to friends, measured at follow-up survey following misinformation exposure and intervention, controlling for baseline pre-intervention/exposure intention. Measured on a 1-10 scale. Higher score means they are more likely to recommend the HIV vaccine to a friend.

2-4 weeks
Credibility of Inoculated Exposure #1
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #2
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #3
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #3 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #4
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #4 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #5
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #5 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #6
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #6 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #1
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #2
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #3
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #3 made the participants anxious or nervous about the HIV vaccine. TThey were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #4
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #4 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #5
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #5 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #6
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #6 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #1
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #7
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #7 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #3
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #3 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #4
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #4 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #5
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #5 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Shareability of Inoculated Exposure #6
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #6 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of Inoculated Exposure #1, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #1 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of Inoculated Exposure #2, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #2 made the participants believe the credibility of the information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Shareability of Inoculated Exposure #1, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #1 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of Inoculated Exposure #2, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Anxiousness of Inoculated Exposure #1, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #1 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of Inoculated Exposure #2, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #2 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Credibility of New Claims, Exposure #12, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #12 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #8, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #8 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #9, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #9 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #10, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #10 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Credibility of New Claims, Exposure #11, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #11 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness o of New Claims, Exposure #12, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #12 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Claim #8, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #8 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #9, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #9 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #10, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #10 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Anxiousness of New Claims, Exposure #11, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #11 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #12, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #12 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #8, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #8 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #9, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #9 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #10, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #10 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Shareability of New Claims, Exposure #11, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #11 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks
Credibility of Inoculated Exposure #7
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #7 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

At the end of the baseline assessment
Anxiousness of Inoculated Exposure #7
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #7 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

At the end of the baseline assessment
Shareability of Inoculated Exposure #2
Ramy czasowe: At the end of the baseline assessment

Extent to which claim #2 made the participants more likely to share information about the HIV vaccine. They were provided information on this claim and how to recognize it as misinformation. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

At the end of the baseline assessment
Credibility of New Claims, Exposure #13, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #13 made the participants believe the credibility of the information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to believe the claim.

2-4 weeks
Anxiousness of New Claims, Exposure #13, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #13 made the participants anxious or nervous about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number indicates more self-reported anxiousness.

2-4 weeks
Shareability of New Claims, Exposure #13, Follow-up
Ramy czasowe: 2-4 weeks

Extent to which claim #13 made the participants more likely to share information about the HIV vaccine. They were not provided prior information on this claim. The scale is measured on 1-7. Higher number means they are more likely to share the claim.

2-4 weeks

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

24 lipca 2025

Zakończenie podstawowe (Rzeczywisty)

16 października 2025

Ukończenie studiów (Szacowany)

1 czerwca 2027

Daty rejestracji na studia

Pierwszy przesłany

7 listopada 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

18 listopada 2024

Pierwszy wysłany (Rzeczywisty)

22 listopada 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

24 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

28 sierpnia 2026

Ostatnia weryfikacja

1 sierpnia 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • 1R01MH132401 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIEZDECYDOWANY

Opis planu IPD

The investigators are still determining the data sharing plan and if we will be sharing IPD yet

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .